CANCER SURGERY AND SCAR PREVENTION - JEL3108
Over half of cancer patients will need surgery as a part of their treatment; most of these surgeries will result in a scar
Cancer surgery often involves tumour resection, where the tumour and its surrounding tissues are removed from the body to treat the patient. This means that almost all patients who have surgery will have a scar. As surgery involves damaging the skin, the scars from tumour resection can have uncomfortable or even painful side effects. They can also act as constant, unwanted reminders of a patient’s cancer treatment. Significant psychological impact has also been reported for patients with scarring and burns, in addition to the existing physical injury and trauma.
It has been estimated that approximately 234 million operations are performed worldwide each year (all indications). Each one of these has led to the formation of a scar. Currently, nothing prevents scar formation, and current treatments vary in their effectiveness and can have side effects. Scars don’t only have consequences related to their cosmetic appearance. They can cause pulling and pain and can impact movement or function – for example decreased flexibility around a joint like a knee or elbow. Additional surgery might also be required if they negatively impact a patient’s quality of life. In 2020 alone, 263,643 scar revision procedures were performed, making it one of the top five reconstruction procedures. In addition to skin corrective surgeries, scar treatment products are also widely adopted.
Carocell Bio’s peptide-based, next-generation approach to promoting healthier healing and skin can help reduce the inflammation contributing to scarring after tumour resection. Through topical application to the skin, it can interrupt the inflammatory cascade – reducing excessive collagen deposition that could lead to visible scarring – and potentially providing safer and novel therapeutic options for patients.
Emerging data from Carocell Bio’s initial study to reduce inflammation after a burn indicate the potential of its lead peptide JEL3108.
Find out more about our therapeutic peptides and how they can reduce inflammation in a host of serious inflammatory diseases.
For further information and access to detailed documentation, please get in touch.